Hospital-level Variation in the Management of Blood Pressure and Low-density Lipoprotein in the Outpatient Hypertensives in China-a Cross Sectional Study

Survey on BP, Lipids and Cardiovascular Risks in the Outpatient Hypertensives and Continuing Medical Education Program

To investigate the proportion, medication use and control rate of metabolic abnormalities such as dyslipidemia in outpatients with hypertension in different levels of hospitals in China. To investigate the gap between guidelines and clinical practices, and analyze the cause. we also set up a continuing medical education program to narrow the gap and the effect of the program will be estimated.

Study Overview

• Status: Unknown
• Conditions: Hypertension; Hyperlipidemia
• Intervention / Treatment: Other: continuing medical education program

• Study Type: Observational
• Enrollment (Anticipated): 21000

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200036
      • Recruiting
      • Cardiology Department in Huashan Hospital
      • Contact: Xiufang Gao, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

outpatients with hypertension in different levels of hospitals in China

Description

Inclusion Criteria:

1. Outpatients from departments of Cardiology, Endocrinology, Nephrology, Neurology, Geriatrics or General Internal Medicine.
2. Diagnosed as hypertension. Diagnostic criteria: 1)The office BP measured at the day of visit and at least one time before that day were above the cut-off values ( ≥140 mmHg SBP and/or ≥90 mmHg DBP); 2)for patients with normal BP at the day of visit, they should have already been given pre-treatment with antihypertensive drugs ≥ 2 weeks.
3. Voluntary participation.

Exclusion Criteria:

1. Patients aged< 18 years old.
2. Patients without a definite diagnosis of hypertension（for instance, if the patient has been taking antihypertensive drugs irregularly, it is difficult to confirm the diagnosis of hypertension）.
3. Patients with a definite diagnosis of secondary hypertension.
4. Patients are diagnosed dyslipidemia with clear cause, such as nephrotic syndrome, severe hypothyroidism, terminal stage of malignancy, etc.
5. Patients are diagnosed end-stage renal disease, hemodialysis, and peritoneal dialysis patients.
6. Patients diagnosed with mental abnormalities who are unable to complete the questionnaire.
7. Patients have once participated in this research during this study cycle（to avoid repeated participation）.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
hypertension	Other: continuing medical education program; educating all the involved doctor the same medical knowledge on hypertension control
dyslipidemia in hypertension	Other: continuing medical education program; educating all the involved doctor the same medical knowledge on hypertension control

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
rate of blood pressure goal achievement	systolic blood pressure<140mmHg and diastolic blood pressure<90mmHg	2017-2020

Collaborators and Investigators

• Sponsor: Huashan Hospital

Publications and helpful links

General Publications

• Xie K, Gao X, Bao L, Shan Y, Shi H, Li Y. The different risk factors for isolated diastolic hypertension and isolated systolic hypertension: a national survey. BMC Public Health. 2021 Sep 14;21(1):1672. doi: 10.1186/s12889-021-11686-9.

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2017
• Primary Completion (Anticipated): December 30, 2020
• Study Completion (Anticipated): December 30, 2020

Study Registration Dates

• First Submitted: March 2, 2019
• First Submitted That Met QC Criteria: March 2, 2019
• First Posted (Actual): March 5, 2019

Study Record Updates

• Last Update Posted (Actual): March 5, 2019
• Last Update Submitted That Met QC Criteria: March 2, 2019
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Lipid Metabolism Disorders; Dyslipidemias; Hyperlipidemias
• Other Study ID Numbers: UPPDATE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No